Mutual of America Capital Management LLC Has $1.56 Million Position in Amedisys, Inc. (NASDAQ:AMED)

Mutual of America Capital Management LLC decreased its holdings in Amedisys, Inc. (NASDAQ:AMED) by 2.6% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 16,855 shares of the health services provider’s stock after selling 445 shares during the quarter. Mutual of America Capital Management LLC owned 0.05% of Amedisys worth $1,561,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AMED. Trexquant Investment LP raised its holdings in shares of Amedisys by 1,317.8% in the 4th quarter. Trexquant Investment LP now owns 87,719 shares of the health services provider’s stock worth $7,964,000 after buying an additional 81,532 shares in the last quarter. Fifth Third Bancorp raised its holdings in shares of Amedisys by 68.1% in the 1st quarter. Fifth Third Bancorp now owns 348 shares of the health services provider’s stock worth $32,000 after buying an additional 141 shares in the last quarter. Teacher Retirement System of Texas acquired a new position in shares of Amedisys in the 1st quarter worth approximately $817,000. M&T Bank Corp acquired a new position in shares of Amedisys in the 1st quarter worth approximately $315,000. Finally, Schonfeld Strategic Advisors LLC raised its holdings in shares of Amedisys by 17.5% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 4,500 shares of the health services provider’s stock worth $409,000 after buying an additional 671 shares in the last quarter. 94.36% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Wall Street Zen cut Amedisys from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 24th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $100.00 price target on shares of Amedisys in a report on Wednesday, April 16th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $100.75.

Amedisys Trading Down 0.0%

AMED stock opened at $97.46 on Monday. The business has a fifty day moving average price of $96.01 and a 200 day moving average price of $93.77. Amedisys, Inc. has a fifty-two week low of $82.15 and a fifty-two week high of $98.95. The stock has a market capitalization of $3.20 billion, a price-to-earnings ratio of 35.96, a P/E/G ratio of 1.32 and a beta of 0.94. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.29 and a quick ratio of 1.29.

Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share for the quarter, beating analysts’ consensus estimates of $1.13 by $0.12. The firm had revenue of $594.78 million during the quarter, compared to analysts’ expectations of $597.43 million. Amedisys had a return on equity of 12.52% and a net margin of 3.79%. The business’s revenue was up 4.1% on a year-over-year basis. During the same period last year, the firm posted $1.03 EPS. Analysts expect that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.